Company
Cantoni Therapeutics B.V.
Cantoni Therapeutics is pioneering the discovery and development of small molecule bisubstrate inhibitors towards nicotinamide N-methyltransferase (NNMT), a novel, unexplored and promising target for obesity and its cardiometabolic complications.
Also known as Cantoni Therapeutics
- Status
- Operatingas of 2026-09-20
- Business model
- B2B
- Headquarters
- Oss, The Netherlands
- Founded
- 2022
Claim, correct or request removal
Record updated 28 September 2026
About
Cantoni Therapeutics is pioneering the discovery and development of small molecule bisubstrate inhibitors towards nicotinamide N-methyltransferase (NNMT), a novel, unexplored and promising target for obesity and its cardiometabolic complications.
Loading relationship preview